UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

OMB APPROVAL

 

OMB Number:  3235-0582

 

Expires:  March 31, 2021

 

Estimated average burden

 

hours per response........7.2

 

FORM N-PX

 

ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY

 

Investment Company Act file number 811- 04889

 

Tekla Healthcare Investors

(Exact name of registrant as specified in charter)

 

100 Federal Street, 19th Floor, Boston, MA

 

02110

(Address of principal executive offices)

 

(Zip code)

 

Laura Woodward

Tekla Healthcare Investors

100 Federal Street, 19th Floor, Boston MA 02110

(Name and address of agent for service)

 

Registrant’s telephone number, including area code: 617-772-8500

 

Date of fiscal year end: September 30

 

Date of reporting period: 7/1/17-6/30/18

 

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss.239.24 and 274.5 of this chapter), to file reports with the Commission, not later than August 31 of each year, containing the registrant’s proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4).  The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

 

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public.  A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number.  Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609.  The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

 

 

 


 

Item 1. Proxy Voting Record.

 


 

Vote Summary

 

ABBOTT LABORATORIES

 

Security

002824100

Meeting Type

Annual

Ticker Symbol

ABT

Meeting Date

27-Apr-2018

Record Date

28-Feb-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

R.J. Alpern

 

 

 

For

 

For

 

 

 

2

R.S. Austin

 

 

 

For

 

For

 

 

 

3

S.E. Blount

 

 

 

For

 

For

 

 

 

4

E.M. Liddy

 

 

 

For

 

For

 

 

 

5

N. McKinstry

 

 

 

For

 

For

 

 

 

6

P.N. Novakovic

 

 

 

For

 

For

 

 

 

7

W.A. Osborn

 

 

 

For

 

For

 

 

 

8

S.C. Scott III

 

 

 

For

 

For

 

 

 

9

D.J. Starks

 

 

 

For

 

For

 

 

 

10

J.G. Stratton

 

 

 

For

 

For

 

 

 

11

G.F. Tilton

 

 

 

For

 

For

 

 

 

12

M.D. White

 

 

 

For

 

For

 

2.

 

Ratification of Ernst & Young LLP as Auditors

 

Management

 

For

 

For

 

3.

 

Say on Pay - An Advisory Vote to Approve Executive Compensation

 

Management

 

For

 

For

 

4.

 

Shareholder Proposal - Independent Board Chairman

 

Shareholder

 

For

 

Against

 

 

ABBVIE INC.

 

Security

00287Y109

Meeting Type

Annual

Ticker Symbol

ABBV

Meeting Date

04-May-2018

Record Date

07-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

Roxanne S. Austin

 

 

 

For

 

For

 

 

 

2

Richard A. Gonzalez

 

 

 

For

 

For

 

 

 

3

Rebecca B. Roberts

 

 

 

For

 

For

 

 

 

4

Glenn F. Tilton

 

 

 

For

 

For

 

2.

 

Ratification of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2018

 

Management

 

For

 

For

 

3.

 

Say on Pay - An advisory vote on the approval of executive compensation

 

Management

 

For

 

For

 

4.

 

Say When on Pay - An advisory vote on the frequency of the advisory vote to approve executive compensation

 

Management

 

1 Year

 

For

 

5.

 

Approval of a management proposal regarding amendment of the certificate of incorporation for the annual election of directors

 

Management

 

For

 

For

 

6.

 

Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting

 

Management

 

For

 

For

 

7.

 

Stockholder Proposal - to Issue an Annual Report on Lobbying

 

Shareholder

 

Against

 

For

 

8.

 

Stockholder Proposal - to Separate Chair and CEO

 

Shareholder

 

For

 

Against

 

9.

 

Stockholder Proposal - to Issue an Annual Compensation Committee Report on Drug Pricing

 

Shareholder

 

Against

 

For

 

 


 

AC IMMUNE SA

 

Security

H00263105

Meeting Type

Special

Ticker Symbol

ACIU

Meeting Date

27-Apr-2018

Record Date

13-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

In the event that at the Extraordinary Shareholders’ Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors

 

Management

 

For

 

N/A

 

2.A

 

Election of Douglas Williams as Member to the Board of Directors

 

Management

 

For

 

N/A

 

2.B

 

Election of Douglas Williams to the Compensation, Nomination & Corporate Governance Committee

 

Management

 

For

 

N/A

 

3.a

 

Vote on Total Non-Performance-Related Compensation for the new Member of the Board of Directors from 27 April 2018 to 30 June 2018

 

Management

 

For

 

N/A

 

3.b

 

Vote on Equity for the new Member of the Board of Directors

 

Management

 

For

 

N/A

 

4.a

 

Share Capital Increase for Institutional Investors

 

Management

 

For

 

N/A

 

4.b

 

Share Capital Increase for Current Shareholders

 

Management

 

For

 

N/A

 

 


 

AC IMMUNE SA

 

Security

H00263105

Meeting Type

Annual

Ticker Symbol

ACIU

Meeting Date

06-Jul-2018

Record Date

23-May-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

A.

 

In the event that at the Annual General Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors

 

Management

 

For

 

N/A

 

1.

 

Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2017

 

Management

 

For

 

N/A

 

2.

 

Appropriation of Loss

 

Management

 

For

 

N/A

 

3.

 

Discharge of the Members of the Board of Directors and the Executive Committee

 

Management

 

For

 

N/A

 

4a.

 

Vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2018 to 30 June 2019

 

Management

 

For

 

N/A

 

4b.

 

Vote on Equity for Members of the Board of Directors

 

Management

 

For

 

N/A

 

4c.

 

Vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2018 to 30 June 2019

 

Management

 

For

 

N/A

 

4d.

 

Vote on Total Variable Compensation for Members of the Executive Committee for the current year 2018

 

Management

 

For

 

N/A

 

4e.

 

Vote on Equity for Members of the Executive Committee

 

Management

 

For

 

N/A

 

5a.

 

Re-election of Martin Velasco as member and Chairman of the Board of Directors

 

Management

 

For

 

N/A

 

5b.

 

Re-election of Peter Bollmann as the Member of the Board

 

Management

 

For

 

N/A

 

5c.

 

Re-election of Friedrich von Bohlen as the Member of the Board

 

Management

 

For

 

N/A

 

5d.

 

Re-election of Andrea Pfeifer as the Member of the Board

 

Management

 

For

 

N/A

 

5e.

 

Re-election of Detlev Riesner as the Member of the Board including granting an exception to the age limit

 

Management

 

For

 

N/A

 

5f.

 

Re-election of Tom Graney as the Member of the Board

 

Management

 

For

 

N/A

 

5g.

 

Re-election of Douglas Williams as the Member of the Board

 

Management

 

For

 

N/A

 

5h.

 

Election of Werner Lanthaler as the Member of the Board

 

Management

 

For

 

N/A

 

6a.

 

Re-election of Tom Graney to the Compensation, Nomination & Corporate Governance Committee

 

Management

 

For

 

N/A

 

6b.

 

Re-election of Martin Velasco to the Compensation, Nomination & Corporate Governance Committee

 

Management

 

For

 

N/A

 

6c.

 

Re-election of Doug Williams to the Compensation, Nomination & Corporate Governance Committee

 

Management

 

For

 

N/A

 

7.

 

Re-election of the independent proxy Bugnion Ballansat Ehrler, represented by Gerald Virieux, avocat, Geneva

 

Management

 

For

 

N/A

 

8.

 

Election of the Auditors, PricewaterhouseCoopers SA, Pully

 

Management

 

For

 

N/A

 

9a.

 

Share Capital Increase for Institutional Investors

 

Management

 

For

 

N/A

 

9b.

 

Share Capital Increase for Current Shareholders

 

Management

 

For

 

N/A

 

 


 

ACADIA HEALTHCARE COMPANY, INC.

 

Security

00404A109

Meeting Type

Annual

Ticker Symbol

ACHC

Meeting Date

03-May-2018

Record Date

09-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.1

 

Election of Director: E. Perot Bissell

 

Management

 

For

 

For

 

1.2

 

Election of Director: Vicky B. Gregg

 

Management

 

For

 

For

 

2.

 

Advisory vote on the compensation of the Company’s named executive officers as presented in the Proxy Statement.

 

Management

 

For

 

For

 

3.

 

Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

 

ACADIA PHARMACEUTICALS INC.

 

Security

004225108

Meeting Type

Annual

Ticker Symbol

ACAD

Meeting Date

06-Jun-2018

Record Date

13-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

Julian Baker

 

 

 

For

 

For

 

 

 

2

Stephen Biggar, M.D PhD

 

 

 

For

 

For

 

 

 

3

Daniel Soland

 

 

 

For

 

For

 

2.

 

To approve an amendment to our 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,700,000 shares.

 

Management

 

For

 

For

 

3.

 

To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting.

 

Management

 

For

 

For

 

4.

 

To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

 

ACCELERON PHARMA INC.

 

Security

00434H108

Meeting Type

Annual

Ticker Symbol

XLRN

Meeting Date

06-Jun-2018

Record Date

09-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1a.

 

Election of Class II Director: Habib J. Dable

 

Management

 

For

 

For

 

1b.

 

Election of Class II Director: Terrence C. Kearney

 

Management

 

For

 

For

 

1c.

 

Election of Class II Director: Karen L. Smith, M.D., Ph.D.

 

Management

 

For

 

For

 

2.

 

To approve, on an advisory basis, the compensation paid to the Company’s named executive officers as disclosed in the proxy statement.

 

Management

 

For

 

For

 

3.

 

To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

 


 

AKEBIA THERAPEUTICS, INC.

 

Security

00972D105

Meeting Type

Annual

Ticker Symbol

AKBA

Meeting Date

14-Jun-2018

Record Date

20-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

Michael D. Clayman

 

 

 

For

 

For

 

 

 

2

Duane Nash

 

 

 

For

 

For

 

 

 

3

Ronald C. Renaud, Jr.

 

 

 

For

 

For

 

 

 

4

John P. Butler

 

 

 

For

 

For

 

 

 

5

Muneer A. Satter

 

 

 

For

 

For

 

 

 

6

Michael S. Wyzga

 

 

 

For

 

For

 

2.

 

Ratification of the appointment of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

 

ALBIREO PHARMA INC.

 

Security

01345P106

Meeting Type

Annual

Ticker Symbol

ALBO

Meeting Date

08-Jun-2018

Record Date

18-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

Ronald H.W. Cooper

 

 

 

For

 

For

 

 

 

2

Anne Klibanski, M.D.

 

 

 

For

 

For

 

 

 

3

Stephanie S. Okey, M.S.

 

 

 

For

 

For

 

2.

 

To approve the Albireo Pharma, Inc. 2018 Equity Incentive Plan.

 

Management

 

For

 

For

 

3.

 

To approve the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan.

 

Management

 

For

 

For

 

4.

 

To ratify the appointment of Ernst & Young LLP as Albireo’s independent registered public accounting firm for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

 

ALDER BIOPHARMACEUTICALS, INC.

 

Security

014339105

Meeting Type

Annual

Ticker Symbol

ALDR

Meeting Date

23-May-2018

Record Date

20-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

Paul B. Cleveland

 

 

 

For

 

For

 

 

 

2

Stephen M. Dow

 

 

 

For

 

For

 

 

 

3

A. Bruce Montgomery

 

 

 

For

 

For

 

2.

 

To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement.

 

Management

 

For

 

For

 

3.

 

To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

 


 

ALEXION PHARMACEUTICALS, INC.

 

Security

015351109

Meeting Type

Annual

Ticker Symbol

ALXN

Meeting Date

08-May-2018

Record Date

12-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

Felix J. Baker

 

 

 

For

 

For

 

 

 

2

David R. Brennan

 

 

 

For

 

For

 

 

 

3

Christopher J. Coughlin

 

 

 

For

 

For

 

 

 

4

Deborah Dunsire

 

 

 

For

 

For

 

 

 

5

Paul A. Friedman

 

 

 

For

 

For

 

 

 

6

Ludwig N. Hantson

 

 

 

For

 

For

 

 

 

7

John T. Mollen

 

 

 

For

 

For

 

 

 

8

Francois Nader

 

 

 

For

 

For

 

 

 

9

Judith A. Reinsdorf

 

 

 

For

 

For

 

 

 

10

Andreas Rummelt

 

 

 

For

 

For

 

2.

 

Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm.

 

Management

 

For

 

For

 

3.

 

Approval of a non-binding advisory vote of the 2017 compensation paid to Alexion’s named executive officers.

 

Management

 

For

 

For

 

4.

 

To request the Board to require an independent Chairman.

 

Shareholder

 

For

 

Against

 

 

ALKERMES PLC

 

Security

G01767105

Meeting Type

Annual

Ticker Symbol

ALKS

Meeting Date

23-May-2018

Record Date

23-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1a.

 

Election of Director: Floyd E. Bloom, M.D.

 

Management

 

For

 

For

 

1b.

 

Election of Director: Nancy L. Snyderman, M.D.

 

Management

 

For

 

For

 

1c.

 

Election of Director: Nancy Wysenski

 

Management

 

For

 

For

 

2.

 

To approve, on an advisory basis, the compensation of the Company’s named executive officers.

 

Management

 

For

 

For

 

3.

 

To hold a non-binding, advisory vote, on the frequency of future advisory votes on the compensation paid to the Company’s named executive officers.

 

Management

 

1 Year

 

For

 

4.

 

To ratify, on a non-binding, advisory basis, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board of Directors to set the independent auditor and accounting firm’s remuneration.

 

Management

 

For

 

For

 

5.

 

To approve the Alkermes plc 2018 Stock Option and Incentive plan.

 

Management

 

For

 

For

 

 


 

ALLERGAN PLC

 

Security

G0177J108

Meeting Type

Annual

Ticker Symbol

AGN

Meeting Date

02-May-2018

Record Date

06-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1a.

 

Election of Director: Nesli Basgoz, M.D.

 

Management

 

For

 

For

 

1b.

 

Election of Director: Paul M. Bisaro

 

Management

 

For

 

For

 

1c.

 

Election of Director: Joseph H. Boccuzi

 

Management

 

For

 

For

 

1d.

 

Election of Director: Christopher W. Bodine

 

Management

 

For

 

For

 

1e.

 

Election of Director: Adriane M. Brown

 

Management

 

For

 

For

 

1f.

 

Election of Director: Christopher J. Coughlin

 

Management

 

For

 

For

 

1g.

 

Election of Director: Carol Anthony (John) Davidson

 

Management

 

For

 

For

 

1h.

 

Election of Director: Catherine M. Klema

 

Management

 

For

 

For

 

1i.

 

Election of Director: Peter J. McDonnell, M.D.

 

Management

 

For

 

For

 

1j.

 

Election of Director: Patrick J. O’Sullivan

 

Management

 

For

 

For

 

1k.

 

Election of Director: Brenton L. Saunders

 

Management

 

For

 

For

 

1l.

 

Election of Director: Fred G. Weiss

 

Management

 

For

 

For

 

2.

 

To approve, in a non-binding vote, Named Executive Officer compensation.

 

Management

 

For

 

For

 

3.

 

To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the Board of Directors, acting through its Audit and Compliance Committee, to determine PricewaterhouseCoopers LLP’s remuneration.

 

Management

 

For

 

For

 

4.

 

To renew the authority of the directors of the Company (the “Directors”) to issue shares.

 

Management

 

For

 

For

 

5A.

 

To renew the authority of the Directors to issue shares for cash without first offering shares to existing shareholders.

 

Management

 

For

 

For

 

5B.

 

To authorize the Directors to allot new shares up to an additional 5% for cash in connection with an acquisition or other capital investment.

 

Management

 

For

 

For

 

6.

 

To consider a shareholder proposal requiring an independent Board Chairman, if properly presented at the meeting.

 

Shareholder

 

Against

 

For

 

 

ALLIQUA BIOMEDICAL, INC.

 

Security

019621200

Meeting Type

Special

Ticker Symbol

ALQA

Meeting Date

13-Sep-2017

Record Date

26-Jul-2017

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

TO RATIFY THE FILING AND EFFECTIVENESS OF THE CERTIFICATE OF AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION FILED WITH THE SECRETARY OF STATE OF THE STATE OF DELAWARE ON MAY 6, 2016 AND THE INCREASE IN THE NUMBER OF SHARES OF AUTHORIZED COMMON STOCK EFFECTED THEREBY.

 

Management

 

For

 

For

 

2.

 

TO APPROVE THE PROPOSAL TO AUTHORIZE THE COMPANY’S BOARD OF DIRECTORS, IN ITS DISCRETION BUT PRIOR TO THE ANNUAL MEETING OF THE COMPANY’S STOCKHOLDERS IN 2018, TO AMEND THE COMPANY’S CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE COMPANY’S COMMON STOCK, AT A RATIO IN THE RANGE OF ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).

 

Management

 

For

 

For

 

3.

 

TO APPROVE AN ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF ANY OF THE FOREGOING PROPOSALS.

 

Management

 

For

 

For

 

 


 

ALLIQUA BIOMEDICAL, INC.

 

Security

019621309

Meeting Type

Special

Ticker Symbol

ALQA

Meeting Date

27-Apr-2018

Record Date

23-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

A proposal to approve the Asset Purchase Agreement, the Asset Sale Transaction and the other transactions contemplated by the Asset Purchase Agreement (“the Asset Sale Proposal”).

 

Management

 

For

 

For

 

2.

 

A proposal to approve, on an advisory, non-binding basis, certain compensation that has, will or may be paid or become payable to the Company’s named executive officers in connection with the asset sale (“the Advisory Proposal”).

 

Management

 

For

 

For

 

3.

 

A proposal to adjourn or postpone the Special Meeting of stockholders, if necessary or appropriate, for the purpose of soliciting additional votes for the approval of the Asset Sale Proposal (“the Adjournment Proposal”).

 

Management

 

For

 

For

 

 

ALLIQUA BIOMEDICAL, INC.

 

Security

019621309

Meeting Type

Annual

Ticker Symbol

ALQA

Meeting Date

26-Jun-2018

Record Date

03-May-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

David Johnson

 

 

 

For

 

For

 

 

 

2

Joseph Leone

 

 

 

For

 

For

 

 

 

3

Gary Restani

 

 

 

For

 

For

 

 

 

4

Jeffrey Sklar

 

 

 

For

 

For

 

 

 

5

Mark Wagner

 

 

 

For

 

For

 

2.

 

Ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

 

ALNYLAM PHARMACEUTICALS, INC.

 

Security

02043Q107

Meeting Type

Annual

Ticker Symbol

ALNY

Meeting Date

10-May-2018

Record Date

15-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1a.

 

Election of Class II Director: Dennis A. Ausiello, M.D.

 

Management

 

For

 

For

 

1b.

 

Election of Class II Director: John K. Clarke

 

Management

 

For

 

For

 

1c.

 

Election of Class II Director: Marsha H. Fanucci

 

Management

 

For

 

For

 

1d.

 

Election of Class II Director: David E.I. Pyott

 

Management

 

For

 

For

 

2.

 

To approve the 2018 Stock Incentive Plan.

 

Management

 

For

 

For

 

3.

 

To approve, in a non-binding advisory vote, the compensation of Alnylam’s named executive officers.

 

Management

 

For

 

For

 

4.

 

To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam’s independent auditors for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

 


 

AMARIN CORPORATION PLC

 

Security

023111206

Meeting Type

Annual

Ticker Symbol

AMRN

Meeting Date

14-May-2018

Record Date

18-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

To re-elect Mr. John F. Thero as a director.

 

Management

 

For

 

For

 

2.

 

To re-elect Mr. Patrick J. O’Sullivan as a director.

 

Management

 

For

 

For

 

3.

 

To hold an advisory (non-binding) vote to approve the compensation of the Company’s “named executive officers” as described in full in the accompanying Proxy Statement.

 

Management

 

For

 

For

 

4.

 

To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors’ remuneration as described in the accompanying Proxy Statement.

 

Management

 

For

 

For

 

 

AMGEN INC.

 

Security

031162100

Meeting Type

Annual

Ticker Symbol

AMGN

Meeting Date

22-May-2018

Record Date

23-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1a.

 

Election of Director: Dr. Wanda M. Austin

 

Management

 

For

 

For

 

1b.

 

Election of Director: Mr. Robert A. Bradway

 

Management

 

For

 

For

 

1c.

 

Election of Director: Dr. Brian J. Druker

 

Management

 

For

 

For

 

1d.

 

Election of Director: Mr. Robert A. Eckert

 

Management

 

For

 

For

 

1e.

 

Election of Director: Mr. Greg C. Garland

 

Management

 

For

 

For

 

1f.

 

Election of Director: Mr. Fred Hassan

 

Management

 

For

 

For

 

1g.

 

Election of Director: Dr. Rebecca M. Henderson

 

Management

 

For

 

For

 

1h.

 

Election of Director: Mr. Frank C. Herringer

 

Management

 

For

 

For

 

1i.

 

Election of Director: Mr. Charles M. Holley, Jr.

 

Management

 

For

 

For

 

1j.

 

Election of Director: Dr. Tyler Jacks

 

Management

 

For

 

For

 

1k.

 

Election of Director: Ms. Ellen J. Kullman

 

Management

 

For

 

For

 

1l.

 

Election of Director: Dr. Ronald D. Sugar

 

Management

 

For

 

For

 

1m.

 

Election of Director: Dr. R. Sanders Williams

 

Management

 

For

 

For

 

2.

 

Advisory vote to approve our executive compensation.

 

Management

 

For

 

For

 

3.

 

To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

4.

 

Stockholder proposal for an annual report on the extent to which risks related to public concern over drug pricing strategies are integrated into our executive incentive compensation.

 

Shareholder

 

Against

 

For

 

 

AMICUS THERAPEUTICS, INC.

 

Security

03152W109

Meeting Type

Annual

Ticker Symbol

FOLD

Meeting Date

07-Jun-2018

Record Date

16-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

Donald J. Hayden, Jr.

 

 

 

For

 

For

 

 

 

2

Craig Wheeler

 

 

 

For

 

For

 

2.

 

Proposal to approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01 per share, that we are authorized to issue from 250,000,000 to 500,000,000

 

Management

 

For

 

For

 

3.

 

Approval of the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool

 

Management

 

For

 

For

 

4.

 

Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018

 

Management

 

For

 

For

 

5.

 

Approval, on an advisory basis, the Company’s executive compensation

 

Management

 

For

 

For

 

 


 

AMPHIVENA THERAPEUTICS, INC

 

Security

N/A

Meeting Type

Written Consent

Ticker Symbol

N/A

Meeting Date

20-Dec-2017

Record Date

N/A

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

Approval of Amended and Restated Certificate of Incorporation

 

Management

 

For

 

For

 

2.

 

Approval of Bridge Loan and Waiver of Right of First Offer

 

Management

 

For

 

For

 

3.

 

Omnibus Resolutions

 

Management

 

For

 

For

 

 

ANTHEM, INC.

 

Security

036752103

Meeting Type

Annual

Ticker Symbol

ANTM

Meeting Date

16-May-2018

Record Date

09-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1a.

 

Election of Director: Lewis Hay, III

 

Management

 

For

 

For

 

1b.

 

Election of Director: Julie A. Hill

 

Management

 

For

 

For

 

1c.

 

Election of Director: Antonio F. Neri

 

Management

 

For

 

For

 

1d.

 

Election of Director: Ramiro G. Peru

 

Management

 

For

 

For

 

2.

 

To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2018.

 

Management

 

For

 

For

 

3.

 

Advisory vote to approve the compensation of our named executive officers.

 

Management

 

For

 

For

 

4.

 

To approve proposed amendments to our Articles of Incorporation to allow shareholders owning 20% or more of our common stock to call special meetings of shareholders.

 

Management

 

For

 

For

 

5.

 

Shareholder proposal to allow shareholders owning 10% or more of our common stock to call special meetings of shareholders.

 

Shareholder

 

Against

 

For

 

 

ARENA PHARMACEUTICALS, INC.

 

Security

040047607

Meeting Type

Annual

Ticker Symbol

ARNA

Meeting Date

13-Jun-2018

Record Date

24-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

Jayson Dallas, M.D.

 

 

 

For

 

For

 

 

 

2

Oliver Fetzer, Ph.D.

 

 

 

For

 

For

 

 

 

3

Jennifer Jarrett

 

 

 

For

 

For

 

 

 

4

Amit D. Munshi

 

 

 

For

 

For

 

 

 

5

Garry A. Neil, M.D.

 

 

 

For

 

For

 

 

 

6

Tina S. Nova, Ph.D.

 

 

 

For

 

For

 

 

 

7

Randall E. Woods

 

 

 

For

 

For

 

2.

 

To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.

 

Management

 

For

 

For

 

3.

 

To approve the amendment and restatement of the Arena Pharmaceuticals, Inc., 2017 Long-Term Incentive Plan to, among other things, increase the number of shares authorized for issuance under the 2017 Long-Term Incentive Plan.

 

Management

 

For

 

For

 

4.

 

To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

 


 

ASCENDIS PHARMA A S

 

Security

04351P101

Meeting Type

Annual

Ticker Symbol

ASND

Meeting Date

29-May-2018

Record Date

19-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

Election of Chairman of the Meeting

 

Management

 

For

 

For

 

2.

 

Report on the Company’s Activities during the Past Year

 

Management

 

For

 

For

 

3.

 

Presentation of Audited Annual Report with Auditor’s Statement for Approval and Discharge of the Board of Directors and Management

 

Management

 

For

 

For

 

4.

 

Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report

 

Management

 

For

 

For

 

5a.

 

Election of Board Member: Albert Cha (Class II)

 

Management

 

For

 

For

 

5b.

 

Election of Board Member: Birgitte Volck (Class II)

 

Management

 

For

 

For

 

5c.

 

Election of Board Member: Martin Olin (Class II)

 

Management

 

For

 

For

 

6.

 

Election of State-authorized Public Auditor

 

Management

 

For

 

For

 

7.

 

Any proposals from the Board of Directors and/or Shareholders: The Board of Directors proposes to renew the authorisation to the Board of Directors to issue warrants. Please refer to the Notice for additional information.

 

Management

 

For

 

For

 

 


 

AURIS MEDICAL HOLDING AG

 

Security

H03579101

Meeting Type

Annual

Ticker Symbol

EARS

Meeting Date

12-Mar-2018

Record Date

09-Feb-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

Approval of the merger between Auris Medical Holding AG (as transferring entity) and Auris Medical NewCo Holding AG (as surviving entity) according to the terms and conditions set forth by the merger agreement dated 9 February 2018 and based on the interim balance sheet of Auris Medical Holding AG as of 30 September 2017. German Version: Genehmigung der Fusion zwischen der Auris Medical Holding AG (als ubertragende Gesellschaft) und der Auris ...(due to space limits, see proxy statement for full proposal).

 

Management

 

For

 

For

 

2.

 

Discharge of liability for the members of the Board of Directors and the Persons entrusted with the Company’s Management. German Version: Entlastung der Mitglieder des Verwaltungsrats und der mit der Geschaftsfuhrung der Gesellschaft betrauten Personen.

 

Management

 

For

 

For

 

3.1

 

Approval of the Compensation of the Board of Directors. German Version: Genehmigung der Vergutung des Verwaltungsrats.

 

Management

 

For

 

For

 

3.2

 

Approval of the Compensation of the members of the Executive Management Committee for the 2019 financial year. German Version: Genehmigung der Vergutung der Geschaftsleitung fur das Geschaftsjahr 2019.

 

Management

 

For

 

For

 

4.1

 

Re-election of Thomas Meyer as member and as Chairman of the Board of Directors. German Version: Wiederwahl von Thomas Meyer als Mitglied und als Prasident des Verwaltungsrats.

 

Management

 

For

 

For

 

4.2

 

Re-election of Armando Anido as member of the Board of Directors. German Version: Wiederwahl von Armando Anido als Mitglied des Verwaltungsrats.

 

Management

 

For

 

For

 

4.3

 

Re-election of Mats Peter Blom as member of the Board of Directors. German Version: Wiederwahl von Mats Peter Blom als Mitglied des Verwaltungsrats.

 

Management

 

For

 

For

 

4.4

 

Re-election of Calvin W. Roberts as member of the Board of Directors. German Version: Wiederwahl von Calvin W. Roberts als Mitglied des Verwaltungsrats.

 

Management

 

For

 

For

 

4.5

 

Election of Alain Munoz as member of the Board of Directors. German Version: Wahl von Alain Munoz als Mitglied des Verwaltungsrats.

 

Management

 

For

 

For

 

5.1

 

Re-election of Armando Anido as member of the Compensation Committee. German Version: Wiederwahl von Armando Anido als Mitglied des Vergutungsausschusses.

 

Management

 

For

 

For

 

5.2

 

Election of Alain Munoz as member of the Compensation Committee. German Version: Wahl von Alain Munoz als Mitglied des Vergutungsausschusses.

 

Management

 

For

 

For

 

6.

 

Re-election of Deloitte AG as Auditors. German Version: Wiederwahl von Deloitte AG als Revisionsstelle.

 

Management

 

For

 

For

 

7.

 

Re-election of the Independent Proxy. German Version: Wiederwahl des unabhangigen Stimmrechtsvertreters.

 

Management

 

For

 

For

 

8.

 

General instruction on new proposals of the Board of Directors. German Version: Allgemeine Weisungen zu nicht angekundigten Antragen / Verhandlungsgegenstanden.

 

Management

 

For

 

For

 

 


 

BEIGENE LTD

 

Security

07725L102

Meeting Type

Annual

Ticker Symbol

BGNE

Meeting Date

06-Jun-2018

Record Date

20-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general ...(due to space limits, see proxy material for full proposal).

 

Management

 

For

 

For

 

2.

 

THAT Michael Goller be and is hereby re-elected to serve as a ...(due to space limits, see proxy material for full proposal).

 

Management

 

For

 

For

 

3.

 

THAT Thomas Malley be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.

 

Management

 

For

 

For

 

4.

 

THAT the BeiGene, Ltd. 2018 Employee Share Purchase Plan be and is hereby approved and adopted.

 

Management

 

For

 

For

 

5.

 

THAT the appointment of Ernst & Young Hua Ming LLP as the Company’s independent registered public accounting firm for the ...(due to space limits, see proxy material for full proposal).

 

Management

 

For

 

For

 

6.

 

THAT, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement for the Meeting, be and is hereby approved.

 

Management

 

For

 

For

 

7.

 

THAT, on a non-binding, advisory basis, future advisory votes on the compensation of the Company’s named executive officers will be held at the frequency hereby approved.

 

Management

 

1 Year

 

For

 

 

BIOCLIN THERAPEUTICS, INC.

 

Security

N/A

Meeting Type

Written Consent

Ticker Symbol

N/A

Meeting Date

27-Sep-2017

Record Date

N/A

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

Election of Director

 

Management

 

For

 

For

 

2.

 

General Authorizing Resolution

 

Management

 

For

 

For

 

 

BIOCLIN THERAPEUTICS, INC.

 

Security

N/A

Meeting Type

Written Consent

Ticker Symbol

N/A

Meeting Date

24-Apr-2018

Record Date

N/A

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

Amendment and Restatement of Restated Certificate of Incorporation

 

Management

 

For

 

For

 

2.

 

Series B Preferred Stock Financing

 

Management

 

For

 

For

 

3.

 

Waiver of Preemptive Rights

 

Management

 

For

 

For

 

4.

 

Notice of Interested Party Transactions

 

Management

 

For

 

For

 

5.

 

Amendment of 2013 Stock and Option Grant Plan

 

Management

 

For

 

For

 

6.

 

General Authorizing Resolution

 

Management

 

For

 

For

 

 


 

BIOCLIN THERAPEUTICS, INC.

 

Security

N/A

Meeting Type

Written Consent

Ticker Symbol

N/A

Meeting Date

21-May-2018

Record Date

N/A

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

Election of Director

 

Management

 

For

 

For

 

2.

 

General Authorizing Resolution

 

Management

 

For

 

For

 

 

BIOGEN INC.

 

Security

09062X103

Meeting Type

Annual

Ticker Symbol

BIIB

Meeting Date

12-Jun-2018

Record Date

17-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1a.

 

Election of Director: Alexander J. Denner

 

Management

 

For

 

For

 

1b.

 

Election of Director: Caroline D. Dorsa

 

Management

 

For

 

For

 

1c.

 

Election of Director: Nancy L. Leaming

 

Management

 

For

 

For

 

1d.

 

Election of Director: Richard C. Mulligan

 

Management

 

For

 

For

 

1e.

 

Election of Director: Robert W. Pangia

 

Management

 

For

 

For

 

1f.

 

Election of Director: Stelios Papadopoulos

 

Management

 

For

 

For

 

1g.

 

Election of Director: Brian S. Posner

 

Management

 

For

 

For

 

1h.

 

Election of Director: Eric K. Rowinsky

 

Management

 

For

 

For

 

1i.

 

Election of Director: Lynn Schenk

 

Management

 

For

 

For

 

1j.

 

Election of Director: Stephen A. Sherwin

 

Management

 

For

 

For

 

1k.

 

Election of Director: Michel Vounatsos

 

Management

 

For

 

For

 

2.

 

To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

3.

 

Say on Pay - To approve an advisory vote on executive compensation.

 

Management

 

For

 

For

 

4.

 

Stockholder proposal requesting certain proxy access bylaw amendments.

 

Shareholder

 

Against

 

For

 

5.

 

Stockholder proposal requesting a report on the extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements.

 

Shareholder

 

Against

 

For

 

 


 

BIOHAVEN PHARMACEUTICAL HLDG CO LTD

 

Security

G11196105

Meeting Type

Annual

Ticker Symbol

BHVN

Meeting Date

01-May-2018

Record Date

26-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1A.

 

Election of Director: Dr. Eric I. Aguiar

 

Management

 

For

 

For

 

1B.

 

Election of Director: Dr. Albert Cha

 

Management

 

For

 

For

 

1C.

 

Election of Director: Ms. Julia P. Gregory

 

Management

 

For

 

For

 

2.

 

Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal year 2018.

 

Management

 

For

 

For

 

 

BIOMARIN PHARMACEUTICAL INC.

 

Security

09061G101

Meeting Type

Annual

Ticker Symbol

BMRN

Meeting Date

05-Jun-2018

Record Date

09-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

Jean-Jacques Bienaime

 

 

 

For

 

For

 

 

 

2

Willard Dere

 

 

 

For

 

For

 

 

 

3

Michael Grey

 

 

 

For

 

For

 

 

 

4

Elaine J. Heron

 

 

 

For

 

For

 

 

 

5

Robert J. Hombach

 

 

 

For

 

For

 

 

 

6

V. Bryan Lawlis

 

 

 

For

 

For

 

 

 

7

Alan J. Lewis

 

 

 

For

 

For

 

 

 

8

Richard A. Meier

 

 

 

For

 

For

 

 

 

9

David E.I. Pyott

 

 

 

For

 

For

 

 

 

10

Dennis J. Slamon

 

 

 

For

 

For

 

2.

 

To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

3.

 

To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement.

 

Management

 

For

 

For

 

 

BLUEBIRD BIO, INC.

 

Security

09609G100

Meeting Type

Annual

Ticker Symbol

BLUE

Meeting Date

20-Jun-2018

Record Date

23-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1a.

 

Election of Class II Director: John O. Agwunobi, M.D.

 

Management

 

For

 

For

 

1b.

 

Election of Class II Director: Mary Lynne Hedley, Ph.D

 

Management

 

For

 

For

 

1c.

 

Election of Class II Director: Daniel S. Lynch

 

Management

 

For

 

For

 

2.

 

To hold a non-binding advisory vote on the compensation paid to the Company’s named executive officers.

 

Management

 

For

 

For

 

3.

 

To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018.

 

Management

 

For

 

For

 

 


 

BLUEPRINT MEDICINES CORPORATION

 

Security

09627Y109

Meeting Type

Annual

Ticker Symbol

BPMC

Meeting Date

20-Jun-2018

Record Date

23-Apr-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1.

 

DIRECTOR

 

Management

 

 

 

 

 

 

 

1

Daniel S. Lynch

 

 

 

For

 

For

 

 

 

2

George D. Demetri, M.D.

 

 

 

For

 

For

 

 

 

3

Lynn Seely, M.D.

 

 

 

For

 

For

 

2.

 

To approve an advisory vote on named executive officer compensation.

 

Management

 

For

 

For

 

3.

 

To hold an advisory vote on the frequency of future advisory votes on named executive officer compensation.

 

Management

 

1 Year

 

For

 

4.

 

Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ended December 31, 2018.

 

Management

 

For

 

For

 

 

BRISTOL-MYERS SQUIBB COMPANY

 

Security

110122108

Meeting Type

Annual

Ticker Symbol

BMY

Meeting Date

01-May-2018

Record Date

14-Mar-2018

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1A.

 

Election of Director: P. J. Arduini

 

Management

 

For

 

For

 

1B.

 

Election of Director: J. Baselga, M.D., Ph.D.

 

Management

 

For

 

For

 

1C.

 

Election of Director: R. J. Bertolini

 

Management

 

For

 

For

 

1D.

 

Election of Director: G. Caforio, M.D.

 

Management

 

For

 

For

 

1E.

 

Election of Director: M. W. Emmens

 

Management

 

For

 

For

 

1F.

 

Election of Director: M. Grobstein

 

Management

 

For

 

For

 

1G.

 

Election of Director: A. J. Lacy

 

Management

 

For

 

For

 

1H.

 

Election of Director: D. C. Paliwal

 

Management

 

For

 

For

 

1I.

 

Election of Director: T. R. Samuels

 

Management

 

For

 

For

 

1J.

 

Election of Director: G. L. Storch

 

Management

 

For

 

For

 

1K.

 

Election of Director: V. L. Sato, Ph.D.

 

Management

 

For

 

For

 

1L.

 

Election of Director: K. H. Vousden, Ph.D.

 

Management

 

For

 

For

 

2.

 

Advisory vote to approve the compensation of our Named Executive Officers

 

Management

 

For

 

For

 

3.

 

Ratification of the appointment of an independent registered public accounting firm

 

Management

 

For

 

For

 

4.

 

Shareholder Proposal on Annual Report Disclosing How Risks Related to Public Concern Over Drug Pricing Strategies are Incorporated into Incentive Compensation Plans

 

Shareholder

 

Against

 

For

 

5.

 

Shareholder Proposal to Lower the Share Ownership Threshold to Call Special Shareholder Meetings

 

Shareholder

 

Against

 

For

 

 


 

CARDINAL HEALTH, INC.

 

Security

14149Y108

Meeting Type

Annual

Ticker Symbol

CAH

Meeting Date

08-Nov-2017

Record Date

11-Sep-2017

 

 

 

Item

 

Proposal

 

Proposed
by

 

Vote

 

For/Against
Management

 

1A.

 

ELECTION OF DIRECTOR: DAVID J. ANDERSON

 

Management

 

For

 

For

 

1B.

 

ELECTION OF DIRECTOR: COLLEEN F. ARNOLD

 

Management

 

For

 

For

 

1C.

 

ELECTION OF DIRECTOR: GEORGE S. BARRETT

 

Management

 

For

 

For

 

1D.

 

ELECTION OF DIRECTOR: CARRIE S. COX

 

Management

 

For

 

For

 

1E.

 

ELECTION OF DIRECTOR: CALVIN DARDEN

 

Management

 

For

 

For

 

1F.

 

ELECTION OF DIRECTOR: BRUCE L. DOWNEY

 

Management

 

For

 

For

 

1G.

 

ELECTION OF DIRECTOR: PATRICIA A. HEMINGWAY HALL

 

Management

 

For

 

For

 

1H.

 

ELECTION OF DIRECTOR: CLAYTON M. JONES

 

Management

 

For

 

For

 

1I.

 

ELECTION OF DIRECTOR: GREGORY B. KENNY

 

Management

 

For

 

For

 

1J.

 

ELECTION OF DIRECTOR: NANCY KILLEFER

 

Management

 

For

 

For

 

1K.

 

ELECTION OF DIRECTOR: DAVID P. KING

 

Management

 

For

 

For

 

2.

 

PROPOSAL TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT AUDITOR FOR THE FISCAL YEAR ENDING JUNE 30, 2018.

 

Management

 

For

 

For

 

3.

 

PROPOSAL TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

 

Management

 

For